- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00970125
Using Video Images to Improve Advance Care Planning in Patients With Cancer
April 28, 2012 updated by: Angelo E. Volandes, MD, Massachusetts General Hospital
The purpose of this study is to study whether preferences for the goals of care for 80 subjects with end-stage cancer are altered after viewing a video outlining the goals of care compared to their initial preferences after hearing a verbal description of the goals of care alone.
Study Overview
Detailed Description
The purpose of this study is to study whether preferences for the goals of care for 80 subjects with end-stage cancer are altered after viewing a video outlining the goals of care compared to their initial preferences after hearing a verbal description of the goals of care alone.
Subjects will choose among three goals of care, life prolonging care, basic medical care, and comfort care.
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Terminal, progressive cancer with poor prognosis whose treatment intent is palliative, based on the following definition:
- All patients with brain cancer, liver cancer, inoperable non-small cell lung carcinoma, pancreatic cancer, or gallbladder cancer; OR
- Patients with the following cancers: metastatic colon cancer or stage III or IV non-small cell lung cancer; OR
- Patients with the following cancers, if first-line therapy has failed and limited response is expected to second-line therapy: breast cancer, colorectal cancer, head and neck cancer, stomach cancer, esophageal cancer, melanoma, leukemia, ovarian cancer, prostate cancer, renal cancer, sarcoma, lung cancer, myeloma, or lymphoma.
- The terms terminal, progressive, poor prognosis, palliative intent and limited response will be judged by the patient's oncologist (and not by the RSA or consenting professional).
- Return patient visit (defined as a patient known to the oncologist from previous assessments and treatments, where the working and personal relationship has been established and not a new patient to the clinic).
- English speaking. Only English-speaking patients will be included in our present study since English is the validated language of our study tools.
- Given the sensitive nature of the study, clinicians will decide whether the patient is a potentially appropriate subject based on their knowledge of the patient.
- Able to provide informed consent.
- Age greater than or equal to 21.
Exclusion Criteria:
- MMSE < 25.
- Psychological state not appropriate for end-of-life discussion as determined by the treating clinician.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cancer subjects
|
outline of the goals of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
end of life preference at time of interview
Time Frame: 5 minutes after survey
|
5 minutes after survey
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
knowledge
Time Frame: 5 minutes after survey
|
5 minutes after survey
|
decisional conflict
Time Frame: 5 minutes after survey
|
5 minutes after survey
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Angelo E. Volandes, MD, MPH, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2009
Primary Completion (Actual)
June 1, 2011
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
August 6, 2009
First Submitted That Met QC Criteria
September 1, 2009
First Posted (Estimate)
September 2, 2009
Study Record Updates
Last Update Posted (Estimate)
May 1, 2012
Last Update Submitted That Met QC Criteria
April 28, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2008-P-002156/2
- R21CA139121-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
University Health Network, TorontoUniversity of UlmRecruiting
Clinical Trials on video
-
National Development and Research Institutes, Inc.UnknownHIV TestingUnited States
-
Medical College of WisconsinCompleted
-
Massachusetts General HospitalFoundation for Informed Medical Decision MakingCompleted
-
Northwestern UniversityCompletedAutism Spectrum Disorder | AutismUnited States
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH)RecruitingDepression | Anxiety | Mobile Phone Use | Health Knowledge, Attitudes, Practice | StigmatizationUnited States
-
Exact Sciences CorporationMayo Clinic; University of Utah; American Cancer Society, Inc.; F!ght Colorectal...Recruiting
-
University of Southern CaliforniaFront Porch Center for Innovation and WellbeingTerminatedMild Cognitive Impairment | Mild DementiaUnited States
-
University of AlbertaStollery Children's HospitalCompletedPediatric ALL | Acute Gastroenteritis | Knowledge TranslationCanada